Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

ADT plus docetaxel or bisphosphonates in hormone sensitive prostate cancer: Systemic review

Dr Claire Vale - MRC Clinical Trials Unit at UCL, London, UK
ADT plus docetaxel or bisphosphonates in hormone sensitive prostate cancer: Systemic review ( Dr Claire Vale - MRC Clinical Trials Unit at UCL, London, UK )
28 Sep 2015

Everolimus for non-functional neuroendocrine tumours

Prof James Yao - University of Texas MD Anderson Cancer Center, Houston, USA
Everolimus for non-functional neuroendocrine tumours ( Prof James Yao - University of Texas MD Anderson Cancer Center, Houston, USA )
26 Sep 2015

TAT 2016: Targeted anticancer therapies

Dr Giuseppe Giaccone - Georgetown University Medical Center, Washington, USA
TAT 2016: Targeted anticancer therapies ( Dr Giuseppe Giaccone - Georgetown University Medical Center, Washington, USA )
19 Jun 2015

Round-up of the latest research on lung cancer

Dr James Spicer - Guy's Hospital, London, UK
Round-up of the latest research on lung cancer ( Dr James Spicer - Guy's Hospital, London, UK )
9 Jun 2015

Enzalutamide preferable to bicalutamide plus LHRH analogue in prostate cancer

Dr Simon Chowdhury - Guy's Hospital, London, UK
Enzalutamide preferable to bicalutamide plus LHRH analogue in prostate cancer ( Dr Simon Chowdhury - Guy's Hospital, London, UK )
9 Jun 2015

Letrozole vs observation for HR positive breast cancer

Dr Nicholas Zdenkowski - University of Newcastle, Newcastle, Australia
Letrozole vs observation for HR positive breast cancer ( Dr Nicholas Zdenkowski - University of Newcastle, Newcastle, Australia )
31 May 2015

Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer

Dr Nicholas Turner - The Institute of Cancer Research, London, UK
Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer ( Dr Nicholas Turner - The Institute of Cancer Research, London, UK )
30 May 2015

Anastrozole offers higher breast cancer-free survival rates than tamoxifen following DCIS

Prof Richard Margolese - The Jewish General Hospital, McGill University, Montreal, Canada
Anastrozole offers higher breast cancer-free survival rates than tamoxifen following DCIS ( Prof Richard Margolese - The Jewish General Hospital, McGill University, Montreal, Canada )
30 May 2015

Effective adjuvant chemotherapy for high-risk, localised prostate cancer

Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA
Effective adjuvant chemotherapy for high-risk, localised prostate cancer ( Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA )
30 May 2015

Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer

Dr Nicholas Turner - The Institute of Cancer Research, London, UK
Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer ( Dr Nicholas Turner - The Institute of Cancer Research, London, UK )
30 May 2015

Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS

Prof Richard Margolese - The Jewish General Hospital, McGill University, Montreal, Canada
Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS ( Prof Richard Margolese - The Jewish General Hospital, McGill University, Montreal, Canada )
30 May 2015

First effective adjuvant chemotherapy for high-risk, localised prostate cancer

Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA.
First effective adjuvant chemotherapy for high-risk, localised prostate cancer ( Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA. )
30 May 2015

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation